NEW YORK (GenomeWeb) – Ambry Genetics said this week that it is adding a new feature to its hereditary cancer risk testing menu: a service called +RNAinsight, which adds RNA sequencing of a group of target genes to the company's existing DNA sequencing panel.

The new offering doesn’t change the cost or turnaround time, which is the same as for the company’s DNA-only testing, said Brigette Davis, Ambry's senior VP of research and development.